To access the differentiation capacity of decitabine, as a DNA methyltransferase inhibitor of tumour cells, we stained cells treated with TMZ in combination with VPA or decitabine for the astrocyte marker GFAP. The gene discussed is GFAP; the disease is neoplasm.